readacross strategi defend humira market
host earn call apr local time humira ex-
us sale yoy vs guidanc declin
biosimilar mainli eu yoy us colleagu estim
eu humira sale bn ex-u vs bn
us aggreg humira biosimilar uptak eu
detail would defend humira market
biosimilar launch new biolog skyrizi upadacitinib etc
initi cover part humira indic ps ra etc
celltrion hc plan launch remsima sc eu
target solidifi posit remicad eu also
expand humira eu drug share mani indic
common ps ra ibd etc celltrion mostli upbeat overtak
ibd patient leverag dual formul conveni
remain cautiou sector despit us team caution view
continu point expect remsima sc
seem high albeit innov one still view upsid
risk skew celltrion hc neutral tp vs celltrion inc
under-perform tp advanc
say eu humira sale track despit biosimilar
uptak host earn call apr local time
humira ex-u sale yoy oper basi ex-
fx impact vs guidanc declin due biosimilar
mainli eu manag said humira eu sale trend within
yoy rang disclos eu breakdown
us colleagu estim eu humira sale bn
ex-u us sale read bn humira sell
drug global view aggreg eu humira biosimilar uptak
mostli driven samsung/biogen
concern uptak expect eu humira sale declin
move sinc expect rise uptak plan
price eros
follow-up product beyond humira
detail would defend humira market
biosimilar
launch new biolog share part humira ten indic
fact announc april fda approv skyrizi
ps plaqu psoriasi inhibitor market soon
also ema review compani expect eu approv soon
also fda review upadacitinib ra rheumatoid
arthriti inhibitor within four month approv timelin per
us colleagu
humira celltrion celltrion
hc cthc plan launch remsima sc eu
ema review cthc target solidifi posit
eu remicad also expand humira eu drug share
mani indic common ps ra ibd etc celltrion mostli
upbeat overtak ibd patient leverag dual formul
contribut indic
figur comparison
administr mainten cycl
rout
europ
alpha biosimilar sale europ
remain cautiou sector besid us team cautiou
view under-perform continu point
expect remsima sc seem high albeit
innov product expand formul sc subcutan
enhanc conveni dual formul iv intraven
yet remsima sc still consid biosimilar eu
us therefor view celltrion address market would find
inflect point plan bring remsima sc
us still view upsid risk skew celltrion hc neutral
tp vs celltrion inc under-perform tp
advanc given anticip new product launch
truxima us remsima sc eu etc
figur celltrion new product launch timelin move part
figur anti-tnf alpha indic brand multipl indic common
figur celltrion address market inflect point
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
ray certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori abbvi inc abbv
signifi initi assumpt coverag
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
charl martineau pm univers toronto price rate histori inc biib oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori celltrion healthcar co ltd
signifi initi assumpt coverag
price rate histori celltrion inc
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
charl martineau pm univers toronto expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
